In vivo efficacy of atorvastatin in the treatment of Tinea pedis: stepping forward into drug repositioning.

Ari Soares de Oliveira Neto, Maria Eliza Samuel Amorim, Rodrigo Luiz Fabri, Rene Oliveira do Couto, Marcelo Gonzaga de Freitas Araújo

Abstract read

PubMed Publisher

In one paragraph

Article in The Journal of antibiotics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ari Soares de Oliveira NetoLaboratory of Pharmacology, Federal University of São João Del-Rei, Campus Centro Oeste Dona Lindu, Divinópolis, MG, Brazil.

Maria Eliza Samuel AmorimLaboratory of Pharmaceutical Development, Federal University of São João Del-Rei, Campus Centro Oeste Dona Lindu, Divinópolis, MG, Brazil.

Rodrigo Luiz FabriBioactive Natural Products Laboratory, Department of Biochemistry, Institute of Biological Sciences, Federal University of Juiz de Fora, Campus, Juiz de Fora, MG, Brazil.

Rene Oliveira do CoutoLaboratory of Pharmaceutical Development, Federal University of São João Del-Rei, Campus Centro Oeste Dona Lindu, Divinópolis, MG, Brazil.

Marcelo Gonzaga de Freitas AraújoLaboratory of Pharmacology, Federal University of São João Del-Rei, Campus Centro Oeste Dona Lindu, Divinópolis, MG, Brazil. mgfaraujo@ufsj.edu.br.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The assignment of new therapeutic purposes to drugs, known as drug repositioning, has been an important ally in the search for new antifungal drugs. Statin compounds, which are used systemically as cholesterol-lowering, may also exert direct antifungal effects, since the statins are drugs that act to prevent sterol synthesis in both humans and fungi and for this reason they are drug promising to combat mycoses. We evaluate the in vivo efficacy of an atorvastatin-loaded topic emulgel (0.75%, 1.5%, or 3.0% m/m) in an in vivo experimental model Tinea pedis. The results showed that the cutaneous delivery-atorvastatin showed total score reduction after seven days of treatment. We concluded that atorvastatin may be a promising drug for the treatment of superficial and cutaneous mycosis.

Indexed as

Antifungal AgentsAtorvastatinDrug RepositioningTinea PedisAdministration, CutaneousAnimalsDisease Models, AnimalAntifungal AgentsAtorvastatin

Identifiers

PMID40670739

DOI10.1038/s41429-025-00848-1

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.